Advertisement
Advertisement
NEUP
Neuphoria Therapeutics Inc. Common Stock
4.00
USDSponsored
-0.01
-0.25%
Feb 05, 15:57 UTC -5
Closed
Pre-Market
3.94
-0.06
-1.38%
NEUP Earnings Reports
Positive Surprise Ratio
NEUP beat 0 of 2 last estimates.
0%
Next Report
Next Week
Date of Next Report
Feb 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$1.49
Implied change from Q1 26 (Revenue/ EPS)
--
/-66.21%
Implied change from Q2 25 (Revenue/ EPS)
--
/--
Neuphoria Therapeutics Inc. Common Stock earnings per share and revenue
On Nov 14, 2025, NEUP reported earnings of -4.41 USD per share (EPS) for Q1 26, missing the estimate of -1.35 USD, resulting in a -225.89% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.84% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of -1.49 USD, with revenue projected to reach -- USD, implying an decrease of -66.21% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
FAQ
What were Neuphoria Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Neuphoria Therapeutics Inc. Common Stock reported EPS of -$4.41, missing estimates by -225.89%, and revenue of $0.00, 0% as expectations.
How did the market react to Neuphoria Therapeutics Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 0.84%, changed from $4.75 before the earnings release to $4.79 the day after.
When is Neuphoria Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 12, 2026.
What are the forecasts for Neuphoria Therapeutics Inc. Common Stock's next earnings report?
Based on 5
analysts, Neuphoria Therapeutics Inc. Common Stock is expected to report EPS of -$1.49 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement